[
  {
    "ts": null,
    "headline": "Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know",
    "summary": "Amgen (AMGN) reached $301.29 at the closing of the latest trading day, reflecting a -1.73% change compared to its last close.",
    "url": "https://finnhub.io/api/news?id=1173cdcf2b64234675e210e588bfc3abfb83f124631019cecf4bc86ebd38a46d",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753739404,
      "headline": "Amgen (AMGN) Stock Falls Amid Market Uptick: What Investors Need to Know",
      "id": 136113490,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) reached $301.29 at the closing of the latest trading day, reflecting a -1.73% change compared to its last close.",
      "url": "https://finnhub.io/api/news?id=1173cdcf2b64234675e210e588bfc3abfb83f124631019cecf4bc86ebd38a46d"
    }
  },
  {
    "ts": null,
    "headline": "Biotech stocks dip as Trump administration mulls patent fee overhaul",
    "summary": "Investing.com -- Biotech stocks fell across the board Monday afternoon, with the SPDR S&P Biotech ETF (NYSE:XBI) dropping to a low of 1.1% after reports emerged that the Trump administration is considering a major overhaul of the U.S. patent system.",
    "url": "https://finnhub.io/api/news?id=62c4a767d17ea9fa389a30852e09a3357654725d5a485cea652900b5d9b1c91a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753733633,
      "headline": "Biotech stocks dip as Trump administration mulls patent fee overhaul",
      "id": 136113491,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Investing.com -- Biotech stocks fell across the board Monday afternoon, with the SPDR S&P Biotech ETF (NYSE:XBI) dropping to a low of 1.1% after reports emerged that the Trump administration is considering a major overhaul of the U.S. patent system.",
      "url": "https://finnhub.io/api/news?id=62c4a767d17ea9fa389a30852e09a3357654725d5a485cea652900b5d9b1c91a"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. stock underperforms Monday when compared to competitors",
    "summary": "Amgen Inc. stock underperforms Monday when compared to competitors",
    "url": "https://finnhub.io/api/news?id=6f3c8d440fc6f9dcbc9516acaf5cece879dc5961f5ad1b86f3ffd4262761f4fd",
    "source": "MarketWatch",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753720560,
      "headline": "Amgen Inc. stock underperforms Monday when compared to competitors",
      "id": 136122910,
      "image": "",
      "related": "AMGN",
      "source": "MarketWatch",
      "summary": "Amgen Inc. stock underperforms Monday when compared to competitors",
      "url": "https://finnhub.io/api/news?id=6f3c8d440fc6f9dcbc9516acaf5cece879dc5961f5ad1b86f3ffd4262761f4fd"
    }
  },
  {
    "ts": null,
    "headline": "2 Top Dividend Stocks to Buy Right Now and Hold Forever",
    "summary": "Long-term shareholders have already seen significant gains from these stocks, and there's likely much more to come for patient investors.",
    "url": "https://finnhub.io/api/news?id=0d7882ccc1bf37cf932ebf4b61c698d9d94625d2aae1be80fc5909c01ec3e19b",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753711200,
      "headline": "2 Top Dividend Stocks to Buy Right Now and Hold Forever",
      "id": 136108046,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Long-term shareholders have already seen significant gains from these stocks, and there's likely much more to come for patient investors.",
      "url": "https://finnhub.io/api/news?id=0d7882ccc1bf37cf932ebf4b61c698d9d94625d2aae1be80fc5909c01ec3e19b"
    }
  },
  {
    "ts": null,
    "headline": "Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick",
    "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
    "url": "https://finnhub.io/api/news?id=2b9db4eeab87a470c011cda6134a3a43afb3c73f50eb10dd70a567a34ecb426c",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753710601,
      "headline": "Are You a Momentum Investor? This 1 Stock Could Be the Perfect Pick",
      "id": 136108298,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.",
      "url": "https://finnhub.io/api/news?id=2b9db4eeab87a470c011cda6134a3a43afb3c73f50eb10dd70a567a34ecb426c"
    }
  },
  {
    "ts": null,
    "headline": "Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know",
    "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=b3ff484ae88f82fb16b7be6785205d67f2047e76fdd22feef13df1f8647c0ffc",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753707602,
      "headline": "Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know",
      "id": 136108299,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen (AMGN) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=b3ff484ae88f82fb16b7be6785205d67f2047e76fdd22feef13df1f8647c0ffc"
    }
  },
  {
    "ts": null,
    "headline": "GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval",
    "summary": "GSK's stable dividend and strong portfolio face modest growth amid competition and legal risks.",
    "url": "https://finnhub.io/api/news?id=f2c1ff55466555a16146f2862081ba3107b08e25c2042e9d05eca444184afeb2",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753706498,
      "headline": "GSK: I Foresee Only Very Modest Upside Here Even If Blenrep Gets FDA Approval",
      "id": 136107253,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/2177313278/image_2177313278.jpg?io=getty-c-w1536",
      "related": "AMGN",
      "source": "SeekingAlpha",
      "summary": "GSK's stable dividend and strong portfolio face modest growth amid competition and legal risks.",
      "url": "https://finnhub.io/api/news?id=f2c1ff55466555a16146f2862081ba3107b08e25c2042e9d05eca444184afeb2"
    }
  },
  {
    "ts": null,
    "headline": "BofA Reiterates a Sell Rating on Amgen (AMGN)",
    "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the top low volatility healthcare stocks to buy now. On July 23, BofA analyst Tim Anderson reiterated a Sell rating on Amgen Inc. (NASDAQ:AMGN) with a $261.00 price target. Anderson reasoned that Amgen Inc. (NASDAQ:AMGN) stock is trading at a premium in comparison to its peers despite the modest […]",
    "url": "https://finnhub.io/api/news?id=365424683f7bd5e696d33b64017b805221fe334472cb79ebd0b94214bf38dbdd",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753682896,
      "headline": "BofA Reiterates a Sell Rating on Amgen (AMGN)",
      "id": 136108300,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) is one of the top low volatility healthcare stocks to buy now. On July 23, BofA analyst Tim Anderson reiterated a Sell rating on Amgen Inc. (NASDAQ:AMGN) with a $261.00 price target. Anderson reasoned that Amgen Inc. (NASDAQ:AMGN) stock is trading at a premium in comparison to its peers despite the modest […]",
      "url": "https://finnhub.io/api/news?id=365424683f7bd5e696d33b64017b805221fe334472cb79ebd0b94214bf38dbdd"
    }
  },
  {
    "ts": null,
    "headline": "BMO Cuts Amgen (AMGN) Price Target After Mixed MariTide Data at ADA Conference",
    "summary": "Amgen Inc. (NASDAQ:AMGN) ranks among the best low volatility stocks to buy according to analysts. While keeping its Outperform rating, BMO Capital lowered its price target for Amgen Inc. (NASDAQ:AMGN) from $346 to $335 on July 9. Amgen’s narrative now “flips commercial” with a further MariTide catalyst not expected until later this year, according to […]",
    "url": "https://finnhub.io/api/news?id=b81f5359c2575c2ee45826732c5b3fdd10fa8b9818c6c583e79d65e4ad5b07df",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753681350,
      "headline": "BMO Cuts Amgen (AMGN) Price Target After Mixed MariTide Data at ADA Conference",
      "id": 136108301,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "AMGN",
      "source": "Yahoo",
      "summary": "Amgen Inc. (NASDAQ:AMGN) ranks among the best low volatility stocks to buy according to analysts. While keeping its Outperform rating, BMO Capital lowered its price target for Amgen Inc. (NASDAQ:AMGN) from $346 to $335 on July 9. Amgen’s narrative now “flips commercial” with a further MariTide catalyst not expected until later this year, according to […]",
      "url": "https://finnhub.io/api/news?id=b81f5359c2575c2ee45826732c5b3fdd10fa8b9818c6c583e79d65e4ad5b07df"
    }
  }
]